Gaush Meditech (HKSE:02407) Research & Development: HK$102 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02407 Gaush Meditech Ltd HKSE:02407
67 GF Score
Price HK$5.29
GF Value HK$13.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gaush Meditech Research & Development?

Gaush Meditech HKSE:02407 +7.30% 67 Research & Development is HK$102 Mil as of Dec. 2025. GuruFocus rates HKSE:02407 with a GF Score™ of 67/100 and a GF Value™ of HK$13.40 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Gaush Meditech's Research & Development for the six months ended in Dec. 2025 was HK$54 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$102 Mil.

Gaush Meditech  (HKSE:02407) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gaush Meditech Research & Development Related Terms

Gaush Meditech Research & Development Historical Data

* Premium members only.

The historical data trend for Gaush Meditech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gaush Meditech Research & Development Chart

Gaush Meditech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 28.78 45.89 57.84 83.73 102.27

Gaush Meditech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.29 37.83 46.21 47.44 54.33
HKSE:02407
67GF Score
Gaush Meditech Ltd HKSE:02407
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gaush Meditech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$102 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$102 Mil mean?
Gaush Meditech (HKSE:02407) has a Research & Development of HK$102 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Gaush Meditech and its competitors.
Is Gaush Meditech's Research & Development too high?
Gaush Meditech's current Research & Development is HK$102 Mil. Overall, Gaush Meditech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Research & Development compare to ABT and SYK?
Gaush Meditech's Research & Development of HK$102 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Gaush Meditech and its competitors. Gaush Meditech's current Research & Development is HK$102 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (HKSE:02407) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.40, compared to a current price of HK$5.29 — trading 60.5% below its estimated fair value. The current Research & Development is HK$102 Mil. Gaush Meditech's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Gaush Meditech (HKSE:02407), the current Research & Development is HK$102 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gaush Meditech (HKSE:02407) Overvalued in 2026?

Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued. The current stock price of HK$5.29 is trading 60.5% below its estimated GF Value™ of HK$13.40. GuruFocus considers Gaush Meditech to be Possible Value Trap.

Key valuation signals for HKSE:02407:

  • Research & Development: HK$102 Mil
  • GF Value™: HK$13.40 vs. price of HK$5.29 (60.5% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the HKSE:02407 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gaush Meditech Business Description

Other Exchanges F7Y:Germany
Address No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
67GF Score

Get the complete analysis for HKSE:02407

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.29
Price
HK$13.40
GF Value